← Evidence map

ArticlePloS one2025

Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022.

Maryo Baakliny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022. | OpenQuestion